Share-based Payment Arrangement, Expense of Coya Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Coya Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • Coya Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,070,892, a 38% increase year-over-year.
  • Coya Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,977,236, a 88% increase year-over-year.
  • Coya Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,663,539, a 205% increase from 2023.
  • Coya Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $872,248, a 321% increase from 2022.
  • Coya Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $207,346, a 11% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Coya Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,977,236 $1,070,892 +$295,886 +38% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $3,681,350 $1,035,713 +$373,392 +56% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $3,307,958 $1,080,082 +$644,419 +148% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $2,663,539 $790,549 +$552,550 +232% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q3 2024 $2,110,989 $775,006 +$512,254 +195% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $1,598,735 $662,321 +$471,211 +247% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $1,127,524 $435,663 +$255,276 +142% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $872,248 $237,999 +$166,570 +233% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $705,678 $262,752 +$192,918 +276% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $512,760 $191,110 +$146,452 +328% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $366,308 $180,387 +$158,962 +742% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $207,346 $71,429 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $69,834 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $44,658 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $21,425 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1

Coya Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,663,539 +$1,791,291 +205% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $872,248 +$664,902 +321% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $207,346 -$25,876 -11% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $233,222 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.